Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
1(33.3%)
N/A
1(33.3%)
Phase 1
1(33.3%)
3Total
Phase 3(1)
N/A(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02359929Phase 1Completed

BMT Autologous MSCs for GvHD

Role: collaborator

NCT02639208Not ApplicableCompleted

Novel Social Media Intervention For Older Br CA Patients

Role: collaborator

NCT00299533Phase 3Completed

Polyunsaturated Fatty Acids for Adjunctive Treatment of Refractory Epilepsy

Role: collaborator

NCT00319722Unknown

EEG Studies of Sensory Processing in Autistic Children

Role: collaborator

All 4 trials loaded